Risk assessment with gut microbiome and metabolite markers in NAFLD development. PC80A309A5
4 studies · 696 curated samples · 521 distinct subject identifiers · 1 shared paper. Grouping rule: shared own-data paper.
Age categories
| adult | 444 |
| unknown | 252 |
Countries
| CN | 696 |
Health conditions
| other_disease Other disease / condition | 252 |
| obesity Obesity / overweight | 138 |
| cardiometabolic_other Other cardiometabolic (hypertension | 86 |
| type2_diabetes Type 2 diabetes / prediabetes | 78 |
| healthy_control Healthy / control | 52 |
Studies
| study | title | samples | source |
|---|---|---|---|
| PRJNA703757 | Human gut microbiota raw sequence reads from resistant starch intervention project in patients with NAFLD | 252 | gut_all_v1 |
| PRJNA686835 | Human gut microbiota Raw sequence reads from medication-naive individuals who are lean or abdominally obese subjects with and without T2D | 182 | gut_all_v1 |
| PRJNA728908 | Gut microbiota of baseline individuals in a 4.6-year non-alcoholic fatty liver disease prospective study | 176 | gut_all_v1 |
| PRJNA414688 | Metagenomic raw reads for gut microbiota from resistant starch project | 86 | gut_all_v1 |
Shared papers
- Risk assessment with gut microbiome and metabolite markers in NAFLD development. — PMID 35675435 · PMC9746350 · doi · studies: PRJNA414688, PRJNA686835, PRJNA703757, PRJNA728908